Introduction
Morphea or Localized scleroderma (LS) is an idiopathic inflammatory disease of the skin characterized by localized, circumscribed sclerotic patches, or plaques with variable pigmentation. LS has been differentiated from systemic sclerosis based upon the clinical findings of almost exclusive cutaneous involvement (typically with some involvement of the underlying musculature) with absence of internal organ involvement. Morphea is associated with systemic manifestations and autoimmunity, but the prevalence of these findings remains unclear.
In patients with LS there is an increased incidence of autoimmune disorders, but few publications have reported the coexistence of celiac disease (CD) and hearing loss (HL) in morphea.
Case Report
A 13-year-old girl born to consanguineous healthy parents presented with a 9-year history of progressive skin change, with hearing loss when she attended primary school. There was no family history of scleroderma or autoimmune disease but her sister was suffering from hearing loss too with non documented skin lesions.
At the age of 4, a reddish-brown lesion was noted on her limbs, the lesion continued to grow. Two years later, hyperpigmentation appeared on large areas of the lower back (Fig. 1) .
By the age of 7, the patient began to experience bilateral flexion contracture of the fourth and fifth fingers (Fig. 2) . Recently, she complained from some episodes of chronic diarrhea.
She denied symptoms of itching, burning, or pain of the skin, breathing difficulties, seizures, cramps, reflux, dysphagia, or Raynaud' s phenomenon.
On physical examination, she was below the 3rd percentile on growth chart for weight and height. Multiple indistinct and vague areas of hyperpigmentation of purple-brown skin were distributed on her limbs, thighs and back. The limbs were of equal length. The flexion contracture of the bilateral fourth and fifth fingers was marked without arthritis. The skin lesions overlying the 4th and 5th fingers bilaterally was normal. The patient was explored for her bilateral hearing loss revealing a sensorineural audiometric hearing impairment.
Laboratory tests showed an elevation of markers of inflammation (ESR> 70mm/ h and C reactive protein at 108mg/l) as well as positive ANA. The other laboratory findings showed malabsorption markers (Iron deficiency anemia, hypocalcaemia and hypoproteinemia) and positive IgA and IgG antigliadin and anti-endomysial antibodies.
The histopathologic findings on the skin biopsy taken together supported a diagnosis of morphea. Jejune biopsy showed unexpectedly severe intestinal atrophy with a moderate lymphoplasmacytic infiltrate in the lamina propria and an increase of the intraepithelial lymphocytes.
Oral corticosteroid therapy was instituted with a combination of methotrexate (0.5 mg/kg/wk) successfully. Four months later, the affected skin softened and the large plaques of hyperpigmentation disappeared. The patient' s gastrointestinal symptoms improved on a gluten-free diet.
Discussion
In this case report, we describe the uncommon coexistence of morphea, hearing loss (HL) and celiac disease (CD) in a young girl.
We were unable to identify previous reports of morphea, CD, and HL in the same patient. Although both morphea and HL have been described in patients with CD [1, 2] , whereas multiple reports have stablished an association between systemic sclerosis (SS) and CD [3] , SS and hearing loss [4] .
LS has been differentiated from systemic sclerosis based upon the clinical findings of almost exclusive cutaneous involvement (typically with some involvement of the underlying musculature) with absence of internal organ involvement. The condition has an estimated incidence of 0.4 to 1 per 100,000 individuals1 [5] .
According to skin lesions, our patient seems to have a generalized morphea. The diagnosis of LS is established on clinical grounds, usually by the physical appearance of the lesions. A biopsy of the skin and/or subcutaneous tissue may be useful for confirmation if there is doubt about the diagnosis.
The prevalence of autoimmune and systemic disease in morphea and its subtypes and the correlation with autoantibody profile remain unclear.
Patients with localized morphea have an increased incidence of auto-immune disorders [6, 7, 8] , but this is not related to the age of onset, duration of disease nor the site or number of lesions. The patients have an increased incidence of tissue antibodies and these are more common when more than one lesion is present [9] .
These findings suggest an immunological basis for the disease and indicate that the patients should be investigated and followed up to detect the evidence of other auto-immune disorders.
In a recent study, Leitenberger et al [10] showed that concomitant rheumatic or other autoimmune disease was significantly more prevalent among adults (29%) than children (3%). Overall, 18% of subjects had a concomitant rheumatic or other autoimmune disorder, an occurrence fourfold higher than that in the general population including all races and socioeconomic strata. But when analyzed by subtype, generalized morphea had a statistically significant association with autoimmune disease with 49% of generalized morphea subjects affected representing 12 times the risk of the general population. Children with morphea were relatively spared of concomitant autoimmune disease (only6% versus 37% of adults) [6] . It is unknown whether children with morphea will develop autoimmune disorders at an increased rate as they reach adulthood.
The most commonly associated diseases include Hashimoto' s thyroiditis, vitiligo, psoriasis, type 1 diabetes mellitus and CD [7, 9] .
Morphea has also been observed as part of an overlap syndrome in association with other connective tissue diseases such as systemic lupus erythematosus, rheumatoid arthritis, Sjögren' s syndrome juvenile dermatomyositis, polymyositis, or eosinophilic fasciitis [6] .
There is no clear cut explanation for this although it is noted that autoimmune diseases may share a genetic background. In addition, an exposure to a common etiological trigger agent is also possible [11] .
The relatives of the patients have also been found to have an increased incidence of auto-immune disorders. In one study, 16 percent of patients reported a positive family history for rheumatic or autoimmune diseases. Significantly more children (22%) than adults (11%) had a family history of a rheumatic or other autoimmune disease in a first or second degree relative . In adults the generalized subtype had the highest frequency of familial disease (22%). In children, mixed (24%) and generalized (22%) had the highest frequency of family history of autoimmunity [10] .
Zulian et al. reported similar findings in a pediatric cohort with a statistically significant association of familial autoimmunity in the generalized subtype [6] .
Similar disorders to those reported in morphea subjects were reported in their family members. Rheumatoid arthritis, systemic lupus erythematosus and psoriasis were observed with the highest frequency in 1st and 2nd degree relatives of morphea patients overall. [6, 9] Multicase families with morphea have been reported independently in the literature were in a non-Mendelian pattern suggestive of a multifactorial, polygenic inheritance [12, 13] .
In our case, there is probably a family history of autoimmune disorders, consolidated by the consanguinity.
Recent epidemiological studies show that the prevalence of CD is underestimated not only in Europe, but also among the populations of Mediterranean regions such as the Middle East and North Africa [14, 15] . Indeed, in these two regions, a very high prevalence of CD has recently been reported both in the general population and in at-risk groups [16] .
The prevalence of CD among the general population varies from 0.14% to 1.17% [17, 18] . Among high-risk groups (including patients with a positive family history, insulin-dependent diabetes mellitus, thyroiditis) the prevalence of CD ranges from 2.4% to 44%, assessed by serological markers and biopsy [19, 20] .
The prevalence of autoimmune disorders is increased in patients with CD, and it is unknown whether their first-degree relatives also have a high risk of autoimmune disorders. These subjects are mainly affected by undiagnosed subclinical or silent clinical forms of CD [21, 22] .
The majority have a normal gluten-containing diet, and it is uncertain whether a prolonged gluten intake increases the risk of AD in persons genetically predisposed to CD [23] .
Two main theories have been postulated to explain this comorbidity: (1) linkage disequilibrium between the genes responsible for celiac disease and those responsible for the coexpressed autoimmune diseases or (2) untreated celiac disease leading to the onset of other autoimmune diseases.
The current literature did not clearly establish which of the two theories explain the comorbidity between celiac disease and other autoimmune disorders. There is, however, growing evidence that the loss of the intestinal barrier function typical of celiac disease could be responsible of the onset of other autoimmune disease. This concept implies that the autoimmune response can be theoretically stopped and perhaps reversed if the interplay between autoimmune predisposing genes and trigger(s) is prevented or eliminated by a prompt diagnosis and treatment [24] Whereas multiple reports have established an association between systemic sclerosis and CD [3] , few publications have reported the coexistence of CD and LS [1] . The gastrointestinal (GI) findings in LS include esophageal motor function abnormalities with gastro-esophageal reflux have been reported in children with LS [11] .
Our case emphasises the importance of studying patients with LS with chronic diarrhea and malabsorption not only by antigliadin, anti-endomysial or antitransglutaminase antibody determination but also, by an intestinal biopsy, in order to clarify the source of the malabsorption, to obtain relief of symptoms, and to improve the prognosis of patients with LS.
Sensorineural hearing loss (SNHL) is a neurological situation and CD may be seen coincidentally. Children with clinical signs of hearing deficiency of unknown etiology should be assessed for CD.
Solmaz et al [2] showed a statistically significant difference between the audiometric results in the CD and control groups (right ear and left ear) (p < 0.05) indicating that there is a need for hearing loss screening in pediatric patients with CD. Hizli et al. [25] observed significantly higher prevalence (40.6%) of SNHL in children with CD than in controls. These signs show that there is a relation between SNHL and CD in pediatric cases. Although hearing loss occurs in the patients, none of the CD cases suffer from hearing impairment. As a consequence early diagnosis is crucial, because insidious hearing loss may bring about a diminishing in sensory motor development, cognitive development, and social and behavioral development [26] . The immunopathogenesis of CD is multifactorial, and SNHL pathogenesis accompanied by pediatric CD may also be multifactorial. Type II and type III immunological reactions would be causing inner ear pathology together in pediatric CD cases. In vitro endomysial antibodies immunofluorescence with cerebral vasculature was demonstrated by Pratesi et al. [27] .
SS can cause hearing loss, tinnitus, vertigo, and patulous Eustachian tube. The hearing loss is sensorineural in most cases and mixed in a small percentage of patients. Hearing impairment in SS primarily affects the high frequencies [4] .
Conclusion
In conclusion, juvenile LS is a challenging but uncommon disorder among children. Autoimmune dysfunction as a contributing cause of LS is supported by many observations.
Various uncommon autoimmune conditions were observed in our patient, and then the patients with juvenile localized scleroderma who have various autoimmune disorders.
Aggregation of autoimmune diseases is frequently observed in clinical practice. There is no clear cut explanation for this although it is noted that autoimmune diseases may share a genetic background. It provides rationale for further research to identify genetic and environmental determinants of autoimmunity. This research may, in time, dramatically change the way autoimmune diseases are classified.
In this patient, organ impairment is similar than that seen in patients with SS; this indicates that juvenile LS and juvenile SS likely represent 2 ends of a continuous disease spectrum (Fig 3) . For this reason, patients with juvenile localized scleroderma should be identified early, evaluated extensively, treated aggressively, and monitored carefully.
This uncertainty negatively impacts patient care as many patients are untreated or treated with skin directed therapy who may in fact require systemic therapy.
Specifically, that patients with generalized should be aggressively monitored for the presence of autoimmune disorders and systemic manifestations and treated with systemic immunosuppressives when indicated. These findings may warrant a re-examination of the current classification of morphea from the perspective of inclusion of extracutaneous disorders.
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